文献速递肝病

美国商业保险跨性别成人肝硬化患者的特征与结局:一项全国队列研究

Characteristics and Outcomes Among US Commercially Insured Transgender Adults With Cirrhosis: A National Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2024-06-25

基于Optum匿名数据库2007至2022年数据,跨性别成人肝硬化患病率高于顺性别成人(每10万人1285 vs 561)。肝硬化跨性别者焦虑、抑郁、HIV/AIDS及酒精和病毒病因比例更高,但死亡、失代偿、肝移植发生率密度及5年生存率与顺性别者相似。

要点

  • 跨性别成人肝硬化患病率为每10万人1285,顺性别为561。
  • 肝硬化跨性别者焦虑70.7%、抑郁66.4%,均高于顺性别者。
  • 两组死亡、失代偿、肝移植发生率密度及5年生存率相似。

核心结论

  • 跨性别成人肝硬化患病率约为顺性别成人的两倍,且多数合并焦虑和/或抑郁诊断。

研究设计与样本

  • 基于Optum匿名Clinformatics Data Mart数据库2007至2022年的全国队列研究,纳入64,615,316名成人,其中跨性别42,471人(0.07%)。
  • 肝硬化患者共329,251人,其中跨性别293人(0.09%);计算年龄标化患病率、发病率密度,并用逆概率治疗加权分析5年生存率。

主要发现

  • 跨性别与顺性别成人肝硬化患病率分别为每10万人1285(95%CI 1,136-1,449)与561(95%CI 559-563)。
  • 肝硬化跨性别者焦虑比例为70.7%(95%CI 56.9-86.9),顺性别者为43.2%(95%CI 42.7-43.8);抑郁为66.4%(95%CI 53.3-81.7)vs 38.4%(95%CI 37.9-38.9)。
  • 肝硬化跨性别者HIV/AIDS比例为8.5%(95%CI 3.9-16.1),顺性别者为1.6%(95%CI 1.5-1.7);酒精病因为57.5%(95%CI 46.0-71.1)vs 51.0%(95%CI 50.5-51.6),病毒病因为30.5%(95%CI 22.8-39.8)vs 24.2%(95%CI 23.9-24.5),病因置信区间有重叠。
  • 跨性别与顺性别者死亡发生率密度分别为每100人年12.0(95%CI 8.8-15.3)与14.0(95%CI 13.9-14.2),失代偿为15.7(95%CI 10.9-20.5)vs 14.1(95%CI 14.0-14.3),肝移植为0.3(95%CI 0.0-0.8)vs 0.3(95%CI 0.3-0.4)。
  • 逆概率治疗加权生存分析中,跨性别与顺性别者5年生存概率分别为63.4%(95%CI 56.6-71.1)与59.1%(95%CI 58.7-59.4)。

临床怎么用

  • 作者认为这些结果可为研究人员、政策制定者和临床医生提供信息,以推进对跨性别个体的公平照护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The National Institute on Minority Health and Health Disparities has noted that transgender individuals experience unique health disparities. We sought to describe the landscape of transgender patients with cirrhosis. METHODS: We identified all transgender and cisgender adults in Optum's deidentified Clinformatics Data Mart Database between 2007 and 2022 using validated billing codes and calculating age-standardized prevalence of cirrhosis among cisgender vs transgender adults. Among those with incident cirrhosis diagnoses, we calculated age-standardized incidence densities of liver-related outcomes (decompensation, transplantation, hepatocellular carcinoma) and all-cause mortality. We examined 5-year survival using inverse probability treatment weighting to balance transgender and cisgender populations on demographic and clinical characteristics. RESULTS: Among 64,615,316 adults, 42,471 (0.07%) were transgender. Among 329,251 adults with cirrhosis, 293 (0.09%) were transgender. Trans- (vs cis-) genders had higher prevalence of cirrhosis (1,285 [95% confidence interval (CI) 1,136-1,449] per 100,000 vs 561 [559-563] per 100,000). Among adults with cirrhosis, trans- (vs cis-) genders had higher proportions of anxiety (70.7% [56.9-86.9] vs 43.2% [42.7-43.8]), depression (66.4% [53.3-81.7] vs 38.4% [37.9-38.9]), HIV/AIDS (8.5% [3.9-16.1] vs 1.6% [1.5-1.7]), and alcohol (57.5% [46.0-71.1] vs 51.0% [50.5-51.6]) and viral (30.5% [22.8-39.8] vs 24.2% [23.9-24.5]) etiologies, although etiologies had overlapping CIs. Trans- (vs cis-) genders had similar incidence densities of death (12.0 [95% CI 8.8-15.3] vs 14.0 [13.9-14.2] per 100 person-years), decompensation (15.7 [10.9-20.5] vs 14.1 [14.0-14.3]), and liver transplantation (0.3 [0.0-0.8] vs 0.3 [0.3-0.4]). In inverse probability treatment weighting survival analysis, transgender and cisgender individuals had similar 5-year survival probabilities (63.4% [56.6-71.1] vs 59.1% [58.7-59.4]). DISCUSSION: Trans- (vs cis-) gender adults have double the prevalence of cirrhosis, and the majority have a diagnosis of anxiety and/or depression. These results are informative for researchers, policymakers, and clinicians to advance equitable care for transgender individuals.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Elhence H, Dodge JL, Kahn JA, et al. Characteristics and Outcomes Among US Commercially Insured Transgender Adults With Cirrhosis: A National Cohort Study. Am J Gastroenterol. 2024. PMID: 38916204. doi:10.14309/ajg.0000000000002907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。